Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802001 | 0.88 | ALOX15 (0.79) | PYGLALOX15FLT3EGFRF7 | |
| SCHEMBL27477013 | 0.85 | FLT3 (0.54) | PYGLFLT3SMYD3RXFP1 | |
| SCHEMBL6163437 | 0.84 | PYGL (0.74) | PYGLALOX15EGFR | |
| SCHEMBL17149697 | 0.83 | ALOX15 (0.63) | PYGLALOX15EGFRF7F3 | |
| SCHEMBL6164201 | 0.82 | PYGL (0.65) | PYGLALOX15EGFR | |
| SCHEMBL29360910 | 0.81 | PYGL (0.88) | PYGLEGFR | |
| SCHEMBL17149621 | 0.81 | ALOX15 (0.60) | PYGLALOX15EGFRF7F3 | |
| SCHEMBL17149725 | 0.81 | ALOX15 (0.60) | PYGLALOX15EGFRF7F3 | |
| SCHEMBL17149892 | 0.80 | FLT3 (0.61) | PYGLALOX15FLT3MEN1KMT2A | |
| SCHEMBL6162883 | 0.79 | PYGL (0.65) | PYGLALOX15EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |